Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876398 | 0.82 | EPHX2 (0.50) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14996187 | 0.81 | EPHX2 (0.53) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL13245899 | 0.80 | EPHX2 (0.49) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL17572000 | 0.79 | EPHX2 (0.43) | EPHX2ALDH1A1EPHX1CPN1CPB2 | |
| SCHEMBL23570940 | 0.78 | EPHX2 (0.47) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14018532 | 0.78 | EPHX2 (0.47) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2423313 | 0.78 | EPHX2 (0.44) | EPHX2ALDH1A1EPHX1 | |
| SCHEMBL8513454 | 0.77 | CPN1 (0.37) | ALDH1A1CPN1CPB2 | |
| SCHEMBL10282539 | 0.77 | ALDH1A1 (0.67) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL7487836 | 0.77 | EPHX2 (0.53) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961256-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | EPHX2 1416/4885ALDH1A1 4022/4885CHRNB2 2501/4885 |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | EPHX2 1664/4885ALDH1A1 4296/4885CHRNB2 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.